	US 12,110,294 B2
	CD73 compounds
Mark J. Bartlett, Castro Valley, CA (US); Gregory F. Chin, San Francisco, CA (US); Michael O. Clarke, Redwood City, CA (US); Jennifer L. Cosman, Foster City, CA (US); Deeba Ensan, Foster City, CA (US); Bindu Goyal, Fremont, CA (US); Stephen Ho, Redwood City, CA (US); Hon C. Hui, San Mateo, CA (US); Richard L. Mackman, Millbrae, CA (US); Michael R. Mish, Foster City, CA (US); Scott D. Schroeder, Union City, CA (US); Nathan D. Shapiro, Belmont, CA (US); Dustin S. Siegel, Half Moon Bay, CA (US); Doris T. Tang, Burlingame, CA (US); and Hai Yang, San Mateo, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Apr. 29, 2021, as Appl. No. 17/243,911.
Claims priority of provisional application 63/149,803, filed on Feb. 16, 2021.
Claims priority of provisional application 63/018,774, filed on May 1, 2020.
Prior Publication US 2023/0039553 A1, Feb. 9, 2023
Int. Cl. C07D 487/04 (2006.01); A61K 45/06 (2006.01); C07D 519/00 (2006.01); C07K 16/28 (2006.01)

CPC C07D 487/04 (2013.01) [A61K 45/06 (2013.01); C07D 519/00 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01)]

7 Claims

1. A compound selected from the group consisting of: